Last €65.86 EUR
Change Today +0.21 / 0.32%
Volume 453.0
NOTA On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
Frankfurt
SIX Swiss Ex
As of 8:27 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NOTA) Snapshot

Open
€64.94
Previous Close
€65.65
Day High
€66.00
Day Low
€64.94
52 Week High
07/7/14 - €67.67
52 Week Low
07/31/13 - €53.14
Market Cap
178.2B
Average Volume 10 Days
169.7
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
€2.74
Dividend Yield
3.06%
Current Stock Chart for NOVARTIS AG-ADR (NOTA)

novartis ag-adr (NOTA) Details

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines. Its Consumer Health division offers over-the-counter medicines comprising readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. The company distributes its OTC products through various channels, such as food, drug, and mass retail outlets, as well as pharmacies; and Animal Health products directly and through wholesalers of veterinary products. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

135,000 Employees
Last Reported Date: 04/24/14
Founded in 1895

novartis ag-adr (NOTA) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.3.1M
Chief Financial Officer
Total Annual Compensation: SFr.747.1K
President of Institutes for Biomedical Resear...
Total Annual Compensation: $1.9M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: $2.0M
Division Head of Animal Health and Member of ...
Total Annual Compensation: SFr.1.4M
Compensation as of Fiscal Year 2013.

novartis ag-adr (NOTA) Key Developments

Microbix Biosystems Inc. Sues Novartis AG for Virusmax Patent Infringement in Europe

Microbix Biosystems Inc. announced that it has sued Novartis AG (NVS) for alleged infringement of its Virusmax patent in Europe. Microbix said it commenced a new patent litigation in the Court of Dusseldorf, Germany against Novartis Vaccines and Diagnostics. The company had earlier filed a complaint against Novartis in the Eastern District of Texas on January 6, 2014, for alleged infringement of the Virusmax patent in the U.S. Microbix' Virusmax technology is used for increasing virus yields in egg-based vaccine manufacture. The patent application was first published internationally in 2004 when the global market for influenza vaccine was $1.6 billion. At that time, there was growing concern about limited global vaccine manufacturing capacity and supply, especially in light of a potential influenza pandemic. According to Microbix, an independent study published in the Journal of Vaccine in 2006 reported that the application of Virusmax technology led to a significant increase in flu virus production in eggs. These trials used methods comparable to those used in seasonal influenza vaccine manufacture. Microbix noted that it has also demonstrated substantial yield increases over conventional manufacturing processes for several influenza vaccine strains using its technology. The company was granted patents for the Virusmax technology in twenty-one countries between 2006 and 2011. Microbix said it successfully defended its European Virusmax patent against Novartis at the European Patent Office in January 2014. Following a hearing in Munich, the European Patent Office rendered a decision in favor of Microbix and confirmed that the Virusmax technology is a novel, useful and non-obvious invention. However, Novartis has now appealed that decision.

Novartis AG's Leukemia Treatment CTL019 Gets FDA Breakthrough Therapy Status

Novartis AG announced that the United States Food and Drug Administration has granted breakthrough therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia. The breakthrough therapy filing was submitted by the University of Pennsylvania's Perelman School of Medicine which has an exclusive global agreement with Novartis to research, develop and commercialize personalized CAR T cell therapies for the treatment of cancers. The FDA Breakthrough Therapy designation is intended to expedite the development and review of new medicines that treat serious or life-threatening conditions if the therapy has demonstrated substantial improvement over an available therapy on at least one clinically significant endpoint.

Sandoz Launches Hypertension and Hypercalcemia Drugs in Japan

Sandoz, the generic pharmaceutical division of Novartis, has launched Valsartan, Losarhyd and zoledronic acid, in Japan. Valsartan and Losarhyd are indicated for the treatment of hypertension and Zoledronic Acid for hypercalcemia of malignancy. Valsartan is a generic version of Novartis' Diovan Tablets, zoledronic acid is a generic version of Novartis' Zometa for i.v. infusion 4mg/5mL and Losarhyd is a generic version of MSD's Preminent Tablets LD.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOTA:GR €65.86 EUR +0.21

NOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.31 USD +0.42
Bayer AG €101.21 EUR 0.00
Gilead Sciences Inc $88.73 USD -0.21
Novo Nordisk A/S kr247.80 DKK 0.00
Procter & Gamble Co/The $81.16 USD -0.45
View Industry Companies
 

Industry Analysis

NOTA

Industry Average

Valuation NOTA Industry Range
Price/Earnings 22.8x
Price/Sales 3.7x
Price/Book 3.1x
Price/Cash Flow 24.8x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.